Business Description
Active Biotech AB
ISIN : SE0001137985
Description
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.59 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.23 | |||||
Debt-to-EBITDA | -0.1 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -0.8 | |||||
3-Year EPS without NRI Growth Rate | -1.4 | |||||
3-Year FCF Growth Rate | -0.6 | |||||
3-Year Book Growth Rate | -13.4 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.65 | |||||
Quick Ratio | 2.65 | |||||
Cash Ratio | 2.35 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29 | |||||
Shareholder Yield % | 0.84 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -257.57 | |||||
ROA % | -143.55 | |||||
ROIC % | -294.14 | |||||
ROC (Joel Greenblatt) % | -883.61 | |||||
ROCE % | -214.72 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 8.74 | |||||
Price-to-Tangible-Book | 8.45 | |||||
EV-to-EBIT | -3.22 | |||||
EV-to-EBITDA | -3.22 | |||||
EV-to-FCF | -3.23 | |||||
Price-to-Net-Current-Asset-Value | 12.67 | |||||
Price-to-Net-Cash | 16.89 | |||||
Earnings Yield (Greenblatt) % | -31.06 | |||||
FCF Yield % | -25.69 |